NeuroVive holds investor roadshow in Lund

NeuroVive is holding a rights issue and invites you to an investor roadshow in Lund on Monday, 1 September 2008. There are a limited number of places left on a first come, first served basis. Besides this roadshow in Lund, NeuroVive has also held one in Helsingborg, and will be holding further roadshows in Stockholm and Ronneby during the issue period.

Investor roadshow in Lund

Date and time: 1 September 2008, 10.00 – 12.00.
Place: Gamla Biskopshuset, Biskopsgatan 1, 223 62 Lund.
Invitations are available on AktieTorget’s website (www.aktietorget.se), under “Market Days”.
To register, see information in invitation above.

Current rights issue

NeuroVive Pharmaceutical AB (publ) is holding a rights issue for up to SEK 15,010,000 prior to being listed on AktieTorget. The subscription period is 11 August – 3 September 2008. The subscription price is SEK 7.60 per share. Before the current issue, NeuroVive was valued at SEK 89,832,000 (pre-money).
NeuroVive's prospectus, folder and subscription form are available on both the company’s website (www.neurovive.se) and that of AktieTorget (www.aktietorget.se).

Smallcap analysis

NeuroVive’s website also includes a Smallcap analysis, which should be noted.

NeuroVive

NeuroVive is involved in research and development into nerve-cell-protecting drugs for treating traumatic brain damage and other neurological damage for which there is currently no effective treatment. NeuroVive has shown that cyclosporine-A, which is a well-known substance registered for other purposes, has powerful nerve-cell-protecting characteristics.

NeuroVive holds approved worldwide patent rights for the protection of nerve cells with cyclosporine-based drugs in patients with acute neurological damage. The company’s first product, NeuroSTAT®, is ready for clinical trials. NeuroVive is also engaged in the advanced research and development of new potential drugs which could protect nerve cells. NeuroVive intends to license products to major pharmaceutical companies for registration and marketing.

For more information contact:

Eskil Elmér
MD and CSO, Neurovive Pharmaceutical AB (publ)

Telefon: + 46 (0)46-288 01 10
eskil(punkt)elmer(snabel-a)neurovive(punkt)se

NeuroVive is involved in research and development into cyclosporine-based drugs, also known as cyclophilin-D inhibitors. The company’s first product, NeuroSTAT®, is now ready for clinical trials in humans. NeuroVive is also involved in advanced research and development into new potential drugs that could protect nerve cells. The company holds broad patent rights to a family of drugs known as cyclosporines. NeuroVive intends to license products to major pharmaceutical companies for registration and marketing.